Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers’ task group on psychedelics and related compounds

Benjamin R. Lewis, Matthew J. Reid, Andrew M. Novick, Kevin Byrne, Mark J. Niciu, Gregory A. Fonzo, Thomas D. Meyer, David Feifel, Rif S. El-Mallakh, Jair Soares, Trisha Suppes, Frederick S. Barrett

Journal of Psychopharmacology

Published online on February 06, 2026

Abstract

Journal of Psychopharmacology, Ahead of Print.
Rationale:Classical psychedelics—a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline—have shown significant promise for the treatment of mental health conditions in recent clinical trials. ...